-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AdkWJIxCkygSMf2FgsFUrG4kWSKMLuh7hCJPzr4eDfMqIpjTo9RxVEXIs0iYu6fJ se7Ho3c/x9RBPBHbbC8vgg== 0001209191-10-051881.txt : 20101027 0001209191-10-051881.hdr.sgml : 20101027 20101027174404 ACCESSION NUMBER: 0001209191-10-051881 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20101027 FILED AS OF DATE: 20101027 DATE AS OF CHANGE: 20101027 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FISHERMAN JASON S CENTRAL INDEX KEY: 0001197540 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34921 FILM NUMBER: 101145738 MAIL ADDRESS: STREET 1: C/O ADVENT INTERNATIONAL CORP STREET 2: 75 STATE ST 29TH FLOOR CITY: BOSTON STATE: MA ZIP: 02104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aegerion Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001338042 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202960116 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1140 ROUTE 22 EAST, SUITE 304 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: (908) 704-1300 MAIL ADDRESS: STREET 1: 1140 ROUTE 22 EAST, SUITE 304 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Aegerion Pharmaceuticals Inc DATE OF NAME CHANGE: 20050906 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2010-10-27 0 0001338042 Aegerion Pharmaceuticals, Inc. AEGR 0001197540 FISHERMAN JASON S 75 STATE STREET, 29TH FLOOR BOSTON MA 02109 1 0 0 0 Common Stock 13 I See Footnote Common Stock 2010-10-27 4 C 0 3565 A 3578 I See Footnote Common Stock 2010-10-27 4 C 0 1245 A 4823 I See Footnote Common Stock 2010-10-27 4 C 0 2286 7.60 A 7109 I See Footnote Common Stock 2010-10-27 4 P 0 739 9.50 A 7848 I See Footnote Series A Convertible Preferred Stock 0.00 2010-10-27 4 C 0 9212 0.00 D Common Stock 3565 0 I See Footnote Series B Convertible Preferred Stock 0.00 2010-10-27 4 C 0 2041 0.00 D Common Stock 1245 0 I See Footnote Senior Suborinated Convertible Promissory Notes 9.50 2010-10-21 4 A 0 17376.48 0.00 D 2011-12-31 Common Stock 2286 17376.48 I See Footnote Senior Subordinated Convertible Promissory Notes 7.60 2010-10-27 4 C 0 17376.48 0.00 D 2011-12-31 Common Stock 2286 0.00 I See Footnote Shares are indirectly beneficially owned as a limited partner of Advent Partners HLS III Limited Partnership. Upon the closing of the Issuer's initial public offering on October 27, 2010, each share of Series A Convertible Preferred Stock (the "Series A Shares") and each share of the Series B Convertible Preferred Stock (the "Series B Shares"), plus accrued dividends, immediately converted into shares of common stock of the Issuer in accordance with the terms of the Issuer's Third Amended and Restated Certificate of Incorporation. The Series A Shares converted on a 1-for-0.38701117412 basis and the Series B Shares converted on a 1-for-0.61027657931 basis. The Series A Shares and the Series B Shares were convertible at any time, at the holder's election, and automatically upon consummation of the Issuer's initial public offering and had no expiration date. Shares acquired upon the closing of the Issuer's initial public offering at the initial public offering price of $9.50 per share. The outstanding principal and accrued and unpaid interest on these senior subordinated convertible promissory notes (the "Convertible Notes") automatically converted into shares of common stock upon the closing of the Issuer's initial public offering, at $7.60 per share, 80% of the Issuer's initial public offering price per share. /s/ Jarlyth H. Gibson, Attorney-in-Fact 2010-10-27 EX-24.4_348829 2 poa.txt POA DOCUMENT POWER OF ATTORNEY Know all by these presents that the undersigned hereby constitutes and appoints Jarlyth H. Gibson and Anna J. Guerin, each of them acting singly, his true attorney-in-fact to: (1) execute for and on behalf of the undersigned, Rule 144 filings, Forms 3, 4, and 5; related to Aegerion Pharmaceuticals, Inc. in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete the execution of any such Rule 144 filings, Forms 3, 4, and 5 and the timely filing of such forms with the United States Securities and Exchange Commission and any other authority; and (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that any document filed pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his/her discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his/her substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with any section of either the Securities Act of 1933 or the Securities Exchange Act of 1934. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 21st day of October 2010. /s/ Jason S. Fisherman Jason S. Fisherman -----END PRIVACY-ENHANCED MESSAGE-----